Health

GHANA TARGETS PRODUCTION OF ITS FIRST LOCALLY MANUFACTURED VACCINE BY 2027 AS THE NATIONAL VACCINE INSTITUTE ADVANCES PLANS TO BOOST LOCAL PHARMACEUTICAL MANUFACTURING

Ghana is targeting the production of its first locally manufactured vaccine, the Tetanus-Diphtheria vaccine, by 2027, according to the National Vaccine Institute (NVI).

 

The initiative forms part of the country’s efforts to strengthen local vaccine manufacturing and reduce dependence on imported vaccines.

 

The NVI Chief Executive, Dr Sodzi Sodzi-Tettey, said Ghana was working towards producing two pharmaceutical products: the Tetanus-Diphtheria vaccine and the Anti-Tetanus Serum.

 

He outlined the targets during the launch of the pharmaceutical manufacturing policy in October.

 

The vaccines are expected to be developed by two Ghanaian companies, Atlantic Lifesciences and DEK Vaccines, which require at least US$100 million to establish and equip their manufacturing facilities.

 

President John Dramani Mahama mentioned the two companies during the commissioning of new vaccine research laboratories at the Noguchi Memorial Institute for Medical Research in Accra on Wednesday.

 

The newly commissioned messenger RNA (mRNA) and protein laboratories will serve as national research facilities for scientists across the country. Ghana is also among five African countries working with mRNA technology for vaccine research.

 

The mRNA platform allows scientists to design and develop vaccines more quickly by instructing cells to produce specific proteins.

 

In August 2025, President Mahama allocated US$50 million to the NVI to support the country’s vaccine manufacturing ambitions.

 

Mahama urges public support for clinical trials

 

Speaking at the commissioning ceremony, President Mahama encouraged Ghanaians to support clinical trials, describing them as essential to developing vaccines locally.

 

“Nobody would do the clinical trials for us to develop vaccines in our country,” he said.

 

He recalled an Ebola vaccine trial that was planned for the Volta Region but was withdrawn after public concerns emerged.

 

The NVI is working with the World Health Organization, with support from the European Union, to strengthen Ghana’s clinical trials system.

 

Government has also earmarked US$1 billion for the pharmaceutical sector under its new economy plan, with the aim of establishing drug and bio-manufacturing hubs.

 

Ghana is expected to spend US$46 million on vaccines for child immunisation this year. The country also intends to finance its own vaccines by 2030, when support from Gavi is expected to end.

 

Local capacity and pharmaceutical development

 

Five scientists who received training in Brussels and Accra will support operations at the new laboratories and transfer their knowledge to other researchers.

 

The scientists were drawn from the Kumasi Centre for Collaborative Research (KCCR), the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), Noguchi Memorial Institute and the University of Health and Allied Sciences.

 

The new pharmaceutical manufacturing policy covers the use of local raw materials, research and development, tax exemptions and financing support for pharmaceutical manufacturers.

 

Atlantic Lifesciences has also been prequalified under the Africa CDC’s pooled procurement system and secured a contract to supply oxytocin across Africa.

 

The planned pharmaceutical hub is expected to help reduce Ghana’s dependence on imported medicines, which currently accounts for about 70 per cent of the country’s pharmaceutical needs.

 

Meanwhile, the NVI is in discussions with a European partner on how the newly established mRNA technology could support research into cancer vaccines.

 

Ghana’s 2027 vaccine production target builds on an earlier achievement in May 2025, when the NVI and Atlantic Lifesciences produced the country’s first biological product, a Snake Venom Anti-Serum.

 

The locally manufactured serum is intended to support treatment for an estimated 10,000 snakebite victims in Ghana each year, with procurement of the product currently underway.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button